Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies

Blood Adv. 2019 Aug 27;3(16):2487-2490. doi: 10.1182/bloodadvances.2019000466.

Abstract

  1. Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy.

  2. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Immunotherapy, Adoptive* / methods
  • Male
  • Middle Aged
  • Molecular Targeted Therapy*
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / immunology*
  • Multiple Myeloma / therapy*
  • Recurrence
  • Retreatment
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological